Cargando…
Glibenclamide and HMR1098 normalize Cantú syndrome‐associated gain‐of‐function currents
Cantú syndrome (CS) is caused by dominant gain‐of‐function mutation in ATP‐dependent potassium channels. Cellular ATP concentrations regulate potassium current thereby coupling energy status with membrane excitability. No specific pharmacotherapeutic options are available to treat CS but I(KATP) cha...
Autores principales: | Houtman, Marien J. C., Chen, Xingyu, Qile, Muge, Duran, Karen, van Haaften, Gijs, Stary‐Weinzinger, Anna, van der Heyden, Marcel A. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346732/ https://www.ncbi.nlm.nih.gov/pubmed/31119887 http://dx.doi.org/10.1111/jcmm.14329 |
Ejemplares similares
-
PA-6 inhibits inward rectifier currents carried by V93I and D172N gain-of-function K(IR)2.1 channels, but increases channel protein expression
por: Ji, Yuan, et al.
Publicado: (2017) -
Development of I(KATP) Ion Channel Blockers Targeting Sulfonylurea Resistant Mutant K(IR)6.2 Based Channels for Treating DEND Syndrome
por: Houtman, Marien J. C., et al.
Publicado: (2022) -
Disease Associated Mutations in K(IR) Proteins Linked to Aberrant Inward Rectifier Channel Trafficking
por: Zangerl-Plessl, Eva-Maria, et al.
Publicado: (2019) -
Three‐dimensional facial morphology in Cantú syndrome
por: Roessler, Helen I., et al.
Publicado: (2020) -
Glibenclamide treatment in a Cantú syndrome patient with a pathogenic ABCC9 gain‐of‐function variant: Initial experience
por: Ma, Alan, et al.
Publicado: (2019)